Naslov
Rhabdomyolysis in kidney transplant patient with COVID-19: possible role of remdesivir and atorvastatin drug-drug-gene interactions

Autori
Fištrek Prlić, Margareta ; Osmanović Barilar, Jelena ; Ganoci, Lana ; Šimičević, Livija ; Božina, Nada

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Book of abstracts. Pharmaca 2022 ; 52 Suppl 2: 140. / - , 2022, 140-140

Skup
10. Hrvatski kongres farmakologije i 1. Hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem

Mjesto i datum
Opatija, Hrvatska, 22.09.2022. - 25.09.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
adverse events ; atorvastatin ; remdesivir ; pharmacogenetics ; rhabdomyolysis

Sažetak
Introduction Because of very variable clinical presentation of Covid-19 and polypharmacy in elderly, sometimes is difficult to distinguish between the drug-drug, disease- drug or drug-drug-gene induced side effects. Description A 63 –year old Caucasian woman with kidney transplant, was hospitalized due to Covid-19 infection. She was treated with remdesivir for 10 days along with meropenem and methylprednisolone. Mycophenolate was excluded for 10 days. Tacrolimus, atorvastatin, ramipril and ezetimibe were continued and furosemide and pantoprazole were added. After discharge, she started to feel muscle weakness in her extremities and laboratory results at admission showed elevated value of creatinine kinase (CK-MM 6975 U/L). CK returned to the normal range in two weeks following the cessation of atorvastatin and ezetimibe. Discussion In this case atorvastatin and remdesivir were the most prominent candidates for drug-drug and drug- drug-gene interactions resulting in elevated CK and rhabdomyolysis. Pharmacogenetic analysis showed that patient was a carrier of inactivating alleles of CYP2D6*1/*4, CYP3A4*1/*22, SLCO1B1 *5/*5. Remdesivir is substrate of CES1, CYP2D6, CYP3A4, OATP1B1(SLCO1B1) and inhibitor of CYP3A4 and SLCO1B1. Atorvastatin is substrate of CYP3A4 and OATP1B1 and can moderately inhibit the CES1 enzyme, the main metabolic pathway of remdesivir. Other concomitantly prescribed drugs, such as ezetimibe, furosemide and proton pump inhibitors could have added to the drug-drug-gene interactions. Conclusions The pharmacogenetic profiling along with the assessment of drug interactions and pharmacokinetics in polypharmacy can significantly contribute to the minimization of the risk of developing side effects especially in a vulnerable subpopulation of patients such as the kidney transplant patients.

Izvorni jezik
Engleski

Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA